Clinical features and outcomes of<i>ALK</i>rearranged non‐small cell lung cancer with primary resistance to crizotinib
Di Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Junling Li(Tianjin Academy of Agricultural Sciences), Puyuan Xing(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Du(Harbin Medical University), Xuezhi Hao(Chinese Academy of Medical Sciences & Peking Union Medical College), Shan Li(Jiujiang University), Yan Zhang(Xinjiang Medical University), Li Liang(Jiangsu University), Zhaohui Zhang(Peking University), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Tao Xin(Harbin Medical University), Yan Wang(National Institute of Biological Sciences, Beijing), Hongge Liang(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 6
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Room temperature NO 2 gas sensor based on porous Co 3 O 4 slices/reduced graphene oxide hybrid
|Sensors and Actuators B Chemical|2018|203
Comprehensive analysis of prognostic immune‐related genes in the tumor microenvironment of cutaneous melanoma
|Journal of Cellular Physiology|2019|111
<p>MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis</p>
|OncoTargets and Therapy|2020|111
PI3K in Cancer: Its Structure, Activation Modes and Role in Shaping Tumor Microenvironment
|Future Oncology|2017|65